Research Article
Impact of Group Asthma Education on Asthma Control and Emergency Room Visits in an Underserved New York Community
Table 2
Demographic and clinical characteristics.
| | Characteristic | n = 88 | n = 21 asthma admissions |
| | Age, years | 58.89 ± 11.08 | 60 ± 8.18 | | Sex | | | | Male | 22 (25%) | 3 (14.2%) | | Female | 66 (75%) | 18 (85.7%) | | Race | | | | Hispanic | 64 (72.7%) | 15 (71.4%) | | African American | 22 (25%) | 6 (28.6%) | | Others | 2 (2.27%) | 0 | | Tobacco, active smoker | 8 (9.09%) | 4 (19.0%) | | Body mass index | 31.60 ± 7.08 | 33.81 ± 7.34 | | Spirometry available | 85 (97%) | | | FeNO | 68 (77%) | | | Severity of asthma based on GINA 2018 | | | | Mild (step 1 or 2) | 16 (18.2%) | 3 (14%) | | Moderate (step 3) | 50 (56.8%) | 12 (57.1%) | | Severe (step 4-5) | 22 (25%) | 6 (28.6%) | | Number of controller medications for asthma | | | | ICS alone | 19 (21.6%) | 3 (14.2%) | | ICS + LABA | 34 (38.6%) | 7 (33.3%) | | ICS + LABA + LAMA | 31 (35.2%) | 11 (52.4%) | | Leukotriene inhibitors | 64 (72.7%) | 21 (100%) | | Theophylline/roflumilast | 8 (9.1%) | 2 (9.5%) | | Long-term systemic steroids | 5 (5.8%) | 3 (14.2%) | | Comorbidities | | | | Obstructive sleep apnea | 16 (18.2%) | 5 (23.8) | | Gastroesophageal reflux | 15 (17.0%) | 5 (23.8) | | Congestive heart failure | 5 (5.7%) | 0 | | Asthma/COPD overlap syndrome | 7 (7.95%) | 4 (19.0%) | | Bronchiectasis | 2 (2.3%) | 1 (4.7%) |
|
|
COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting beta2-adrenergic agonists; LAMA, long-acting muscarinic agents.
|
